Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL

• ClinicalTrials.gov Identifier: NCT00504751
• Recruitment Status: Completed
• First Posted: July 20, 2007
• Results First Posted: April 7, 2017
• Last Update Posted: April 7, 2017
• Sponsor: Weill Medical College of Cornell University
• Collaborator: Millennium Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Weill Medical College of Cornell University

Study Description

Brief Summary:

Objectives

The primary objective of this study is to:

• determine the complete and partial response rates and the toxicity profile of bortezomib (VELCADE, formerly PS-341) when administered in combination with DICE chemotherapy plus rituximab (i.e. VIPER) to patients with relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma

The secondary objectives of this study are to:

• assess event free survival and overall survival
• assess conversion of chemo-resistant to chemo-sensitive disease
• assess the ability to collect stem cells from patients treated with salvage VIPER who then undergo autologous stem cell transplantation
• perform correlative studies on pre-treatment tumor biopsy specimens; analyses will include the assessment of immunohistochemical expression patterns (germinal center B cell vs. activated B cell) and NF-κB activity

Condition or disease	Intervention/treatment	Phase
Non-Hodgkin's Lymphoma	Drug: bortezomib, dexamethasone, ifosfamide; Drug: mesna, cisplatin, etoposide, rituximab	Phase 2

Detailed Description:

Single arm phase II trial of combination therapy bortezomib, DICE, and Rituximab in patients with relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma (NHL)

VIPER chemotherapy will be administered every 28 days at the following doses:

• Dexamethasone 40 mg IV days 1-4
• Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4
• Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)
• Cisplatin 25 mg IV days 1-4
• Etoposide 100 mg/m2 CIVI over 24 hours days 1-4
• Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)
• VELCADE 1.5 mg/m2 on days 2 and 5

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 15 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Trial of "VIPER" Chemotherapy in Relapsed and Refractory Diffuse Large B-cell Lymphoma (NHL)
• Actual Study Start Date: May 2007
• Actual Primary Completion Date: December 2010
• Actual Study Completion Date: February 17, 2012

Arms and Interventions

Arm

Intervention/treatment

Experimental: Study Treatment; This is a single arm study

Drug: bortezomib, dexamethasone, ifosfamide; VIPER chemotherapy will be administered every 28 days at the following doses: Dexamethasone 40 mg IV days 1-4; Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4; Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide); Cisplatin 25 mg IV days 1-4; Etoposide 100 mg/m2 CIVI over 24 hours days 1-4; Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles); VELCADE 1.5 mg/m2 on days 2 and 5; Drug: mesna, cisplatin, etoposide, rituximab; VIPER chemotherapy will be administered every 28 days at the following doses: Dexamethasone 40 mg IV days 1-4; Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4; Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide); Cisplatin 25 mg IV days 1-4; Etoposide 100 mg/m2 CIVI over 24 hours days 1-4; Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles); VELCADE 1.5 mg/m2 on days 2 and 5

Outcome Measures

Primary Outcome Measures :

1. Complete Response [ Time Frame: 26 months ]
   Complete Response

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of CD20 positive, diffuse large B-cell NHL; de novo or transformed histologies are acceptable
• Patient must have relapsed after or not responded to at least one standard, upfront multi-agent chemotherapy for DLBCL
• Measurable PET positive disease, as defined by tumor mass > 1.5 cm in one dimension
• Stage II, III, or IV disease
• Age > 18 years
• Adequate liver and kidney function (total bilirubin < 2 x ULN and creatinine < 2.0 mg/dl, unless abnormalities are related to lymphoma or Gilbert's disease
• Adequate bone marrow reserves (absolute neutrophil count >1500 cells/mm3 and platelet count > 100,000, unless cytopenias are the result of marrow infiltration by lymphoma
• ECOG performance status < 2
• Life expectancy of at least 3 months
• Bortezomib-naive
• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
• Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
• Male subject agrees to use an acceptable method for contraception for the duration of the study.

Exclusion Criteria:

• Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment.
• Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
• Patient has hypersensitivity to boron or mannitol
• Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. (Pregnancy testing is not required for post-menopausal or surgically sterilized women)
• Patient has received other investigational drugs or cytotoxic chemotherapy within 14 days of enrollment
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• Known HIV infection
• Active Hepatitis B or C as defined by positive Hepatitis B surface antigen or hepatitis C RNA
• Known CNS disease
• Pregnant or nursing women
• Concurrent treatment with other chemotherapy or anti-lymphoma therapy, including corticosteroids, unless on a stable dose of corticosteroids less than the equivalent of 20 mg of prednisone each day for treatment of disease not related to lymphoma
• Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
• Any condition that, in the opinion of the investigator, would prevent the subject from being fully compliant with the protocol.

Contacts and Locations

Locations

United States, New York

Weill Cornell Medical College

New York, New York, United States, 10021

Sponsors and Collaborators

Weill Medical College of Cornell University

Millennium Pharmaceuticals, Inc.

Investigators

• Principal Investigator: Richard Furman, MD; Weill Medical College of Cornell University

More Information

• Responsible Party: Weill Medical College of Cornell University
• ClinicalTrials.gov Identifier: NCT00504751
• Other Study ID Numbers: 0701008963
• First Posted: July 20, 2007
• Results First Posted: April 7, 2017
• Last Update Posted: April 7, 2017
• Last Verified: February 2017

Keywords provided by Weill Medical College of Cornell University:

diffuse large b cell

Additional relevant MeSH terms:

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Dexamethasone; Rituximab; Etoposide; Bortezomib; Ifosfamide; Antineoplastic Agents; Anti-Inflammatory Agents; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Immunologic Factors; Antirheumatic Agents; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors